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The clinical problem
Local regional recurrences of breast cancer may be the cause of
severe suffering when uncontrolled, without being life-threatening
at short term. Symptoms such as ulceration, bleeding and severe
pain have been seen in 62% of the patients with recurrent breast
cancer referred for radiotherapy (RT) (Bedwinek et al, 1981a).
Furthermore, watching a growing tumour at the surface of the
body is a stressful experience to the patient. The survival of
patients with a locoregional recurrence appears not to be related to
any local treatment; in the majority of patients, distant metastasis
is identified after a median follow-up time of less than 12—30
months. Nevertheless, the median survival time in this patient
group may vary from 12 to 53 months, depending mainly on
tumour characteristics at the time of first diagnosis, with a 5-year
survival rate of 22—50% (Bedwinek et al, 1981b; Toonkel et al,
1983; Patanaphan et al, 1984; Aberizk et al, 1986; Deutsch et al,
1986; Hietanen et al, 1986; Stadler and Kogelnik, 1987; Blanco et
al, 1990; Schwaibold et al, 1991; Halverson et al, 1992). The
financial cost of treating patients with local regional breast cancer
recurrences has been estimated to be around Australian $533 per
month by Hurley et al (1992). Therefore, application of a treat-
ment which can result in long-term local tumour control would be
worthwhile from the perspectives of both the patient and the health
care system.
In the case of a recurrent tumour within a previously irradiated
area, the chance of achieving local control by either RT or
chemotherapy is reduced (Okunieff et al, 1991). The radiation
dose that can be given without a high risk of unacceptable toxicity
is lower than considered adequate (Bedwinek et al, 1981a;
Halverson et al, 1990; Withers et al, 1995). This poor prognosis
led to the evaluation of combining re-RT and local hyperthermia
(HT) in this patient group at the DHCC.
Experimental research has shown that HT is an effective cell-
killing agent especially to cells in a hypoxic, nutrient deprived and
low pH environment, conditions which are specifically found in
malignant tumours. The combination of RT with HT should result
in at least a complementary tumoricidal effect, if not a supra-addi-
tive effect (Field, 1990; Raaphorst, 1990). The existing clinical
data appear to confirm the findings from experimental research.
Recently, the therapeutic gain by HT in addition to RT, has been
documented by randomized comparative studies in various tumour
types (Valdagni et al, 1988; Overgaard et al, 1995; International
Collaborative Hyperthermia Group, 1996; van der Zee et al, 1996).
At the DHCC, both treatment modalities underwent changes
during the period since the combination was first applied clinically.
The total re-RT dose gradually increased from about 20 to 32 Gy.
The treatment schedule of eight fractions of 4 Gy, twice weekly, was
first applied in 1981, and, after apparent effectiveness and tolerance
(van der Zee et al, 1988), this became the protocol in 1988.
Hyperthermia technique was gradually improved over the years.
MATERIALS AND METHODS
Patients and tumours
All 134 patients with recurrent adenocarcinoma of the breast, for
whom reirradiation with eight fractions of 4 Gy combined with HT
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Netherlandswas planned between January 1981 and May 1992 for a total
number of 143 fields, are included in this evaluation. Only the first
treated field in each patient was included, leaving a total number
of 134 fields in 134 patients to be analysed. Six of these patients
had been included in the randomized study reported by the
International Collaborative Hyperthermia Group (1996).
Patients were selected for re-RT plus HT on the following
criteria: recurrent tumour, inoperable (n = 119) or after microscopi-
cally incomplete excision (n = 15); and systemic therapy was either
inadequate to control the local regional tumour, or was deemed
inappropriate, in the absence of (symptomatic) systemic disease.
At the time of treatment, patients were aged 28—82 years, with a
median of 58 years. Performance status was generally good, with
WHO scores 0 or 1 in 132 patients and 2—4 in two patients. Distant
metastasis was present at the start of treatment in 38% of the
patients. Seventy per cent of the patients had been treated with
hormonal and/or chemotherapy in the past. Previous RT to the
same area had been given 4 months to 17 years (median 41
months) before the re-RT plus HT treatment. Tumour localization
was on the chest wall in 130 patients. Patient and tumour charac-
teristics known to have prognostic value are given in Table 1, in
relation to the HT technique used for treatment. In case of multiple
lesions, the maximum diameter and the volume of the largest
lesion was used in the evaluation. Tumour volume was calculated
according to the formula 1/6pa*b*c, in which a and b are the
largest diameters measured by calipers and c is the maximum
extension in depth estimated by palpation and, in some cases,
established by ultrasound or computerized tomography (CT) scan.
484 J van der Zee et al
British Journal of Cancer (1999) 79(3/4), 483–490 © Cancer Research Campaign 1999
Table 1 Patient and tumour characteristics in relation to treatment technique
433 MHz n = 107 2450 MHz n = 27
Median (range) s.d.a Patients Median (range) s.d.a Patients
Disease-free interval from start of first
treatment to first relapse (months) 23 (1–158) 27 15 (2–168) 25
Number of previously given kinds of chemotherapy
0 57 9
1 33 13
2 or 3 17 5
Number of previously given kinds of hormonal therapy
0 54 10
1 23 8
³2 30 9
Number of previous surgical procedures at the same
location
0 71
1 49 16
³2 51 10
Dose of radiotherapy given previously (Gy) 45 (20–66) 6 45 (15–58) 10
Macroscopic tumour
≤3c m 38 11
>3 cm 57 13
Ulcerating tumour 24 6
Tumour histology: grade of differentiation
Good 10
Moderate 18 1
Poor 53 12
Undifferentiated 14 7
Unknown 21 7
Number of lesions
Single 42 9
2 19 8
3–9 or more 46 10
Haemoglobin at time of treatment (mmol l–1) 8.3 0.7 8.3 0.7
Tumour outside treatment volume 41 10
Macroscopic tumours only:
Tumour volume (cm3) 11 (1–868) 166 6 (1–777) 39
Tumour maximum diameter (cm) 4.9 (5–300) 6.0 4.7 (6–175) 4.8
Maximum depth (cm) 2.0 (1–9) 1.6 2.0 (1–5) 0.7
Continuation of hormonal therapy during local
treatment 15 5
as.d., standard deviation.Treatment
All patients were treated with the same radiation schedule of 4 Gy
twice weekly, each fraction followed by 1 h HT. The time interval
between two re-RT + HT treatments was 3—4 days, that between
the re-RT fraction and HT session was an average of 40 min. A
summary of treatment characteristics is given in Table 2.
Radiotherapy
The planned treatment of eight fractions of 4 Gy was applied to
129 patients. Four patients received a lower total dose, of 12—
28 Gy, as their treatment was terminated because of general deteri-
oration by rapid progression of systemic disease. In one patient,
the treatment was interrupted because of development of a urinary
tract infection, and a ninth fraction was given to compensate for
the delay. Radiation techniques included electrons (n = 107),
photons (n = 15), a combination (n = 9) or orthovoltage (n = 2)
(unknown in one) depending on the tumour location and depth.
The radiation field was chosen with a margin of at least 2 cm
around the macroscopic tumour.
Hyperthermia
Seven patients received less HT treatments than RT fractions. Four
patients received seven instead of eight HT treatments because of
logistics. In two patients, the treated area needed four HT appli-
cator set-ups to cover the whole field, therefore only half of the
field was treated during each session. In the one patient receiving
nine fractions of RT, six HT treatments were applied. Standard
treatment duration was 60 min with power on. For delivery of HT,
the 2450-MHz technique was used in 27 patients (1981—86) and
the 433-MHz technique in 107 patients (since 1986). The aim of
the treatment was to achieve the highest tumour temperatures.
Power input was limited by the temperatures measured within the
tumour periphery (maximum 44°C was allowed at †1 cm distance
from normal tissue) and the normal tissue (maximum 43°C during
the first 30 min, 44°C during the second 30 min), and by power-
related pain expressed by the patient at a site without thermometry.
The hyperthermia field size is defined as the sum of the aperture
areas of the applicators used.
2450 MHz technique
Custom-built air-filled waveguide applicators, with aperture sizes of
8 ´ 4 and 8 ´ 6c m 2, were used in various combinations. Up to four
applicators were coupled to one power supply, without the possibility
to control power supply to the individual applicators. A maximum of
eight applicators could be used at the same time. Surface cooling,
when necessary, was performed by directing air currents under the
applicators. Interstitial thermometry was performed by thermo-
couples, using either single sensor probes within a needle or multi-
sensor probes within a catheter. Temperatures were measured every
5 min with the power shut off.
433 MHz technique
A dipole antenna was used in three patients. Custom-built water-
filled waveguide applicators (Van Rhoon et al, 1998) were used
since February 1985. The maximum number of applicators used
simultaneously increased, over time, from two to five. Each appli-
cator was supplied with independent power control. Until July
1987, the aim of the treatment was to heat the macroscopic tumour
but, after experiencing tumour regrowth within the radiation field,
outside the margin of the HT field (van der Zee et al, 1992); the
applicator set-up was chosen such that the radiation field was
widely covered. Surface temperature control was performed by
using a perfused water bolus. Since May 1987, temperatures have
Results of reirradiation and hyperthermia in breast cancer 485
British Journal of Cancer (1999) 79(3/4), 483–490 © Cancer Research Campaign 1999
Table 2 Treatment characteristics
n Range Median (s.d.a)
Total re-RT dose
<32 (12–28) Gy 4
=32 Gy 129
=36 Gy 1
Size of radiation field (cm2) 30–875 248 (184)
Size of hyperthermia field (cm2) 64–800 300 (155)
Number of HT applicator set-ups
1 101
2 7
3 2
4 2
Received eight HT treatments 123
Total duration of all HT treatments (min) 480 (55)
Number of thermometry points [median (range)]: 433 MHz 2450 MHz
In tumour tissue 5.4 (1–20) 2.6 (1–10)
In normal tissue 13.9 (1–44) 2.9 (1–11)
HT dose parameters [median (s.d.a)]: 433 MHz 2450 MHz
Tmaxmaxmean in tumour (°C) 43.4 (1.3) 42.2 (1.4)
T90best in tumour (°C) 40.1 (1.2) 40.6 (1.7)
Tmaxmaxmean in normal tissue (°C) 43.8 (1.0) 42.2 (1.2)
T90best in normal tissue (°C) 39.2 (1.1) 39.9 (1.2)
Tumour tissue T90 >40°C (min) 61 (118) 118 (137)
Normal tissue T90 >40°C (min) 0 (55) 48 (101)
as.d., standard deviation.been measured continuously during treatments by a 24-channel
scanning fibre-optic system (FT1210, Takaoka Japan), with which
five multisensor probes (up to four sensors) and four single-sensor
probes were available.
Two patients, both with a tumour extending to a depth of more
than 5 cm, who were treated with other equipment (13.5 MHz
capacative and 80 MHz radiative, respectively) were included in
the 433-MHz technique group.
Hyperthermia dose parameters
For both normal tissue and tumour tissue, 20 parameters represen-
tative of HT dose were calculated from the temperatures measured
during heating. A full description of all these dose parameters is
beyond the scope of this report, but will be published elsewhere.
These parameters, however, appeared highly correlated. Factor
analysis was used to select the two parameters, within tumour as
well as normal tissue, that contain the most information. These
parameters were Tmaxmaxmean and T90best. Tmaxmax is defined as
the highest temperature measured for each heat session and, for this
analysis, the average of these highest temperatures was selected.
T90 is calculated from the Gaussian distribution of all temperature
measurements during each heat treatment, after the heating-up
phase of 10 min, and represents the value above which 90% of all
measurements were observed. The T90best is the T90 from the treat-
ment session during which the highest value was achieved.
End points
Response was established at the time of maximum regression which
was observed 1—14 (median 2) months after start of treatment. A
complete response (CR) is defined according to WHO criteria: clin-
ically a complete tumour remission, observed twice with a time
interval of at least 4 weeks. The duration of local control, in patients
treated for microscopic tumour and in patients in whom a CR was
achieved, was defined from the start of treatment till the first obser-
vation of progression within the treated volume, which is defined as
the volume to which radiation was applied.
Acute toxicity observed can be distinguished to result from
either RT or HT. Radiation-induced acute toxicity includes
erythema (none, mild, moderate or severe) and moist desquama-
tion. Thermal burns include second and third degree burns in the
skin, and subcutaneous burns. Late radiation toxicity was scored
for pigmentation, telangiectasis, subcutaneous fibrosis and ulcera-
tion. Only ulcerations observed without persistent or progressive
tumour, and not resulting from a third degree thermal burn, were
assessed as re-RT toxicity.
Statistical methods
The parameters included in the evaluation of prognostic factors are
listed in Table 3. The evaluation of factors associated with CR was
restricted to the 119 patients with macroscopic tumour. Patients
treated after irradical resection of recurrent tumour were included
in the analysis of local tumour control. Pearson￿s chi-squared test
was used to determine which parameters were associated with CR
rate or acute toxicity caused by the treatment. Cox regression,
univariate as well as multivariate, was used to investigate which
variables were associated with duration of local control.
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Table 3 Parameters included in the evaluation of prognostic factors
Chemotherapy Former chemotherapy: yes or no
Hormonal therapy Former hormonal therapy: yes or no
Former local treatment Two classes: either a maximum of one surgical treatment plus RT, or two or more surgical treatments plus RT
RT dose Total (cumulative) dose of previously applied RT; continuous variable, or classes ≤42, >42–46 and ³46 Gy
Number of lesions Number of tumour lesions within the treatment volume; classes 1, 2 and ³3
Log tumour volume Logarithm of volume of (largest) tumour lesion in mm3; continuous variable, or classes ≤2, 2–4 and ³4
Tumour maximum diameter Maximum diameter of (largest) tumour lesion; in two classes ≤3 and >3 cm
Tmaxmaxmean in tumour Continuous variable, or classes ≤42.5, >42.5–43.5 and ³43.5°C
T90best in tumour Continuous variable, or classes ≤39.6, >39.6–40.6, and >40.6°C
Tmaxmaxmean in normal tissue Continuous variable, or classes ≤43.3, >43.3–44.3, and >44.3°C
T90best in normal tissue Continuous variable, or classes ≤38.8, >38.8–39.5 and >39.5°C
HT technique Two classes: 433 MHz and 2450 MHz
Table 4 Complete tumour response and acute toxicity in relation to
treatment technique
433 MHz 2450 MHz
technique technique
n = 107 (%) n = 27 (%)
Complete response (macroscopic disease only) 74 58
Max. tumour diameter ≤3c m 8 7 9 1
Max. tumour diameter >3 cm 65 31
Local control (microscopic disease included) 76 63
Burns
No or first degree 71 33
Second degree 19 56
Third degree 7 11
Subcutaneous 3 0
Erythema
None–mild 65 59
Moderate–marked 35 41
Moist desquamation 12 7
For both techniques, the difference in CR rate between small and larger
tumours is significant (P = 0.017 for the 433-MHz technique and P = 0.003
for the 2450-MHz technique). The difference in CR rate between the two
techniques is significant for the large tumours (P = 0.024).RESULTS
Complete response and duration of local control
The follow-up time for all patients varied from 1 to 76 months
with a median of 21 months. Five patients died within 4 weeks
after the last treatment, and three patients were lost to follow-up of
the locally treated area because of tumour progression outside the
treatment volume for which they were treated in another hospital.
These eight formally non-evaluable patients were included as non-
complete responders. A CR was observed in 84 out of 119 (71%)
of patients with a macroscopic tumour. The probability to achieve
a CR appeared higher for patients treated with the 433-MHz tech-
nique (74%) than for those treated with the 2450-MHz technique
(58%) (Table 4).
In 26% (n = 35) of all patients, local tumour control was not
achieved. Within the group of 99 patients with CR, or treated after
microscopically incomplete resection, in-field tumour regrowth
was observed in 36, after a follow-up time of 2 months to 5 years
(median 11 months). The median overall survival in these patients
was 20 months. Thirty-six patients have died with local tumour
control after a median survival of 15 months, whereas 27 patients
are still alive with local tumour control after a follow-up period of
5—76 months (median 31 months). Overall, the median duration of
local control, censored for death, is 32 months.
The median overall survival time for the whole group of patients
is 21 months. In the 99 patients in whom local control was
achieved, the median overall survival is 31 months.
Local tumour control in patients with microscopic
disease
Fifteen patients with microscopic disease after incomplete excision
were all treated with the planned re-RT of eight fractions of 4 Gy.
Three of these patients were treated with the 2450-MHz technique.
In all three patients, in-field tumour regrowth was observed 10—12
months after the start of treatment. In the 12 patients treated with
the 433-MHz technique, in-field tumour regrowth was observed
only twice, 10—13 months after the start of treatment. Three patients
have died with local tumour control after 4—16 (median 10) months
and seven patients are still alive with local tumour control after
16—70 (median 42) months. The difference in local control proba-
bility between the two techniques is significant (P < 0.01).
Acute and late toxicity
The skin reaction resulting from re-RT was moderate to marked
erythema in 48 patients, combined with moist desquamation in 15
patients. In 86 patients, the skin reaction was less severe.
Thermal burns developed in 49 patients. In three patients, all
treated with the 433-MHz technique, these were located subcuta-
neously. There was a remarkably lower number of second and
third degree thermal burns in patients treated with the 433-MHz
technique (27%), compared with the patients treated with the
2450-MHz technique (67%) (Table 4). Second-degree burns
generally healed within 2 months without treatment. Third-degree
burns required 4—6 months of conservative treatment to heal. As
these burns preferably develop at sites of limited sensitivity, they
generally caused minimal symptoms.
Clinically relevant late toxicity was observed in a minority of
patients. Part of the late effects of RT had been present before the
start of the combined treatment, because of the previous radiation.
Moderate pigmentation was observed in three patients, moderate
telangiectasis in three, and subcutaneous fibrosis in 19.
Ulcerations were found in 14 patients, nine of whom had this
ulceration at the tumour site before treatment. Ulceration without
persistent tumour was present at last follow-up in five patients. In
three of these patients, this was at the site of a HT-induced burn. In
two patients, the ulceration resulted from radiation damage: one in
the axilla where at the start of the combined treatment severe
telangiectasis was present because of previous irradiation with
50 Gy, and a second in a patient treated for an ulcerating tumour in
the intact breast who had severe fibrosis because of previous RT
(60 Gy). Bone necrosis, fracture or brachial plexopathy were not
observed.
Prognostic factors
Influencing complete response and duration of local control
The probability of achieving a CR decreased if patients had been
previously treated with chemotherapy (P < 0.01) or hormonal
therapy (P < 0.02), had larger tumour volumes (P < 0.01) and had
larger maximum tumour diameters (P < 0.001). Further, the CR
rate increased with higher Tmaxmaxmean in normal tissue
(P < 0.04). Neither the T90best values, for both normal (P = 0.62)
and tumour tissue (P = 0.30), nor the Tmaxmaxmean in tumour
tissue (P = 0.29) showed an association with CR.
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Figure 1 Duration of local control in relation to technique used for delivery
of hyperthermia: 2450 MHz or 433 MHz. Actuarial local control rates at 1 and
2 years are 44% and 33% for 2450 MHz and 54% and 47% for 433 MHz
respectively (log-rank test P = 0.05)
Figure 2 Duration of local tumour control in relation to tumour size:
maximum tumour diameter ≤3 cm compared with >3 cm. Actuarial local
control rates at 1 and 2 years are 69% and 57% for smaller tumours and
36% and 33% for larger tumours respectively (log-rank test P = 0.0001)Univariate Cox regression was used to determine factors that
were of influence to continuous duration of local control. Factors
influencing local control negatively were previous chemotherapy
(P = 0.01), a higher number of lesions (P = 0.02), a larger tumour
volume (P = 0.01) and a larger maximum tumour diameter
(P < 0.001). A higher tumour T90best (P = 0.02) and a higher normal
tissue Tmaxmaxmean (P = 0.02) improved local control duration. It is
to be noted that in the univariate Cox regression there was no
significant difference in local control between patients treated with
2450 MHz and 433 MHz equipment (P = 0.08).
All parameters significant in the univariate regression were
tested in the multivariate analysis, which further included HT
technique. The multivariate Cox regression analysis showed that
tumour maximum diameter, divided into two classes (†3 cm and
>3 cm), appeared to be an independent, significant (P < 0.001)
item with regard to local control, and that 433 MHz equipment
performed better than 2450 MHz equipment (P = 0.046). None of
the other factors was significantly associated with local control.
Figures 1 and 2 show the percentages of local control for
2450 MHz compared with 433 MHz equipment, and maximum
tumour diameter smaller than or equal to 30 mm compared with
larger than 30 mm.
Influencing hyperthermia damage
The only parameter influencing risk of burns was the technique used
for delivery of HT. Univariate logistic regression showed that 433
MHz treatments caused much less acute damage (P < 0.001) than
2450 MHz treatments. Neither the T90best nor the Tmaxmaxmean
thermal dose parameters for both normal and tumour tissue influ-
enced hyperthermia-induced damage (P-values varying between
0.19 and 0.52). None of the evaluated parameters were associated
with late damage.
DISCUSSION
Treatment with a radiation dose of only 32 Gy in combination with
hyperthermia resulted in a complete response in 71% of the
patients with macroscopic tumours. With RT alone at doses of
30—40 Gy, CR rates varying from 20% to 48% have been reported
for breast cancer (van der Zee and Vernon, 1996). The same RT
schedule of eight fractions of 4 Gy without HT has been applied
in the RTOG 81-04 study, resulting in overall 26% complete
response (Perez et al, 1989). Recently, the contribution of HT to
the result of the combined treatment has been confirmed by a
randomized study (International Collaborative Hyperthermia
Group, 1996). Within the ESHO 5-88, comparing re-RT alone
(same schedule as applied in the present study) with re-RT plus
HT, the CR rate after combined treatment was 78%, which was
significantly higher than the 38% CR after re-RT alone. This
randomized study also demonstrated that the difference in local
control is durable.
We do not expect that a locally controlled chestwall recurrence
will influence overall survival. Nevertheless, the absence of symp-
tomatic local tumour can result in an improvement in quality of
life (Liu et al, 1996). When a CR has been achieved, the median
duration of local control was 32 months. In 27% of all patients, in-
field tumour regrowth was observed after a median follow-up time
of 11 months. The median overall survival time in this group of
patients was 20 months, which means that the local palliation was
maintained for half of the remaining life span. Twenty-seven per
cent of the patients have died without local tumour regrowth, after
a median follow-up time of 15 months, whereas 20% of the
patients were free of local disease at last follow-up after a median
follow-up time of 31 months.
Therefore, the effect of the treatment is worthwhile for the
majority of patients, whereas the treatment causes limited incon-
venience. The overall duration of a treatment series is 3.5—4
weeks, during which period patients come to the hospital twice
weekly for around 2 h. The HT treatment is generally well toler-
ated. During treatment, patients were instructed to report pain
immediately; in fact this ￿subjective thermometry￿ is a very impor-
tant parameter in treatment control and should not be considered a
side-effect of HT. The interstitial catheters for thermometry gener-
ally do not cause relevant problems (van der Zee et al, 1987).
The side-effects of the treatment are acceptable; the HT-induced
burns generally cause no pain because of their occurrence at sites
of decreased sensitivity. Side-effects other than thermal burns
were no different than those expected from re-RT alone, i.e.
erythema and, in about 10% of the patients, moist desquamation.
Clinically relevant treatment-related late toxicity was observed in
only five patients, with ulceration due to either HT or RT toxicity.
The indication to offer combined treatment to patients after
incomplete resection of their recurrence was similar to that for
patients with macroscopic tumours: the safe re-RT dose is inade-
quate for tumour control. For achievement of high local control
rates with elective radiation, a dose of about 50 Gy in 2-Gy frac-
tions is required (Bedwinek et al, 1981a; Withers et al, 1995). Our
results in this subgroup demonstrate that additional HT at an
adequate level is beneficial for these patients. Although the
numbers are small, the percentage of patients treated with the 433-
MHz technique in whom local control was maintained is signifi-
cantly higher compared with patients treated with the 2450-MHz
technique. This difference cannot be explained by a better patient
selection. A comparison of the time interval between the primary
RT and re-RT between the 2450-MHz and 433-MHz technique
groups showed no difference. Another indication of a beneficial
effect of HT in microscopic disease is the previous observation of
re-recurrences in five patients in which HT was applied to the
macroscopic tumour only, within the re-RT-alone part of the
treated area (van der Zee et al, 1992).
The results achieved with the 433-MHz technique are remark-
ably better than those achieved with the 2450-MHz technique.
Multivariate Cox regression of prognostic parameters showed only
two parameters to be associated with local control duration, i.e.
tumour size and HT technique. The advantage of using 433 MHz
or, in two cases, lower frequencies instead of 2450 MHz is that with
the lower frequencies the penetration depth, and thereby the heated
volume, is larger, which can be expected to result in an adequate
temperature increase in a larger part of the tumour volume. The
improvement in temperature distribution cannot be deduced from
the thermal dose parameters calculated, which may be explained by
the higher number of intratumour temperature measurements with
the 433-MHz technique compared with the 2450-MHz technique
(van der Zee et al, 1993). The improvement of results with the
better heating technique in tumours with a maximum diameter of
>3 cm underscores that it is important to use a technique from
which one can expect adequate tissue heating. In fact, the 31% CR
rate achieved in the larger (‡3 cm maximum diameter) tumours
with the 2450-MHz technique is not different from the CR rates
found after re-RT alone with the same treatment schedule, i.e. 26%
(Perez et al, 1989) and 38% (International Collaborative Hyper-
thermia Group, 1996). The importance of hyperthermia treatment
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results of the study presented here have shown that there is room for
further improvement. In patients treated with the 433-MHz tech-
nique, the CR rate of 65% in patients with larger tumours is still
significantly lower than that for patients with smaller tumours. We
speculate that when optimum HT techniques will be available for
all tumours, the overall CR rate may reach a value of about 90%.
The decrease in HT-related toxicity with the use of the 433-MHz
technique is another welcome improvement. Although blisters and
third-degree burns generally do not result in relevant clinical prob-
lems, because of the fact that these develop at sites of decreased
sensitivity, it is preferable to avoid such side-effects. The most
likely explanation of the lower number of burns with the 433-MHz
technique is the better control of superficial temperatures by the
perfused water bolus.
This study allows a few more answers to clinically relevant
questions, which have to be precautious in view of the retrospec-
tive character of the analysis. In the first place, it has been
suggested that local therapy for recurrent breast cancer should be
accompanied by systemic therapy (Kapp, 1996). It has been shown
that systemic treatment after local treatment significantly
improved disease-free survival, but had no impact on overall
survival (Borner et al, 1994). In our study, continuation of
chemotherapy during the local treatment series was not allowed,
but in 18 patients with macroscopic tumours hormonal therapy
was continued. The CR rate in patients continuing hormonal
therapy was (not significantly) higher than in the remaining
patients: 89% compared with 67%. However, the risk of selection
bias in this comparison is obvious: 75% of the patients continuing
hormonal therapy had started this more than 2 months previously,
indicating that the therapy had beneficial effects. These patients,
therefore, may represent a subgroup with a better prognosis.
Secondly, tumour extension in depth is considered a very impor-
tant selection criterion for superficial hyperthermia. We now
accept patients with tumours up to 4 cm maximum depth for treat-
ment with 433 MHz. In this study, there were 13 patients with
deeper tumours. The CR rate in these patients of 62% is not signif-
icantly lower than the 72% in the remaining patients, and appears
higher than observed after RT alone. This may be explained by the
exceptions that we have allowed to the maximum 4-cm depth
criterion. These were tumours with overlying subcutaneous fat, in
which less energy is absorbed than in tissues with a high water
content, and spherical tumours protruding above the skin surface,
in which accumulation of energy from the various applicators can
be expected at depth and in which the depth may decrease during
the treatment period when the tumour regresses. A third clinically
important question is whether the eight fractions of 4 Gy plus HT
schedule can be applied after previous RT, up to a total dose of
60 Gy or more. In our material, the CR rate of 50% in a subgroup
of eight such patients seemed lower than the 76% in the remaining
patients, and a persistent ulcer developed in one patient. Further,
this subgroup appeared to have a relatively short remaining life-
time compared with the other patients. Nevertheless, the 50%
chance to achieve a CR may be worthwhile, depending on the
symptoms of local disease and survival prognosis.
CONCLUSIONS
This study has shown that with the combination of re-RT, eight
fractions of 4 Gy in 4 weeks, and HT successful palliation of local
tumour recurrence of a worthwhile duration can be achieved in the
majority of patients. In addition, this treatment is well tolerated
with acceptable toxicity. In The Netherlands, this combined treat-
ment is standard therapy offered to patients with locoregional
recurrent breast cancer in a previously irradiated site, providing
that an adequate heating equipment is available. This study has
also shown that the hyperthermia treatment technique is important
for clinical outcome. The development of better HT treatment
techniques, enabling a more effective treatment of larger tumours,
deserves further investigations.
ACKNOWLEDGEMENTS
The skills and care of the HT technicians MP Broekmeyer-Reurink,
EM Verloop-van ￿t Hof and physics assistant J Stakenborg form a
contributing factor to both the good patient tolerance and the treat-
ment results which should not be underestimated.
The cooperation in this study of other radiation oncologists
(formerly) at the DHCC (AD Treurniet-Donker, JJ Seldenrath, JH
Meerwaldt, SK The, BA Reichgelt, WAM Mellink, AJ Subandono
Tjokrowardojo, PLA van den Ende, PCM Koper, MJM van
Mierlo, and B Veeze-Kuijpers) and from other centres (MFH
Dielwart and JM Tabak, Zeeuws Radiotherapy Institute,
Vlissingen; FH Hoekstra, Westeinde Hospital, The Hague; RJL
Caspers, University Hospital, Leiden; JJ Jobsen and M van Reyn,
Medisch Spectrum Twente Enschede) is highly appreciated.
The clinical work would not have been possible without the
financial support by the Dutch Cancer Society, grants no. EUR 77-
4, RRTI 83-4 and DDHK 93-603, the Maurits and Anna de Kock
Foundation, the Nijbakker Morra Foundation, Willem H Kr￿ger
Foundation, the Foundation Bevordering Volkskracht and the
Foundation Promesa, for which the authors wish to express their
gratitude.
REFERENCES
Aberizk WJ, Silver B, Henderson IC, Cady B and Harris JR (1986) The use of
radiotherapy for treatment of isolated locoregional recurrence of breast cancer
after mastectomy. Cancer 58: 1214—1218
Bedwinek JM, Fineberg B, Lee J and Ocwieza M (1981a) Analysis of failures
following local treatment of isolated local-regional recurrence of breast cancer.
Int J Radiat Oncol Biol Phys 7: 581—585
Bedwinek JM, Lee J, Fineberg B and Ocwieza M (1981b) Prognostic indicators in
patients with isolated local-regional recurrence of breast cancer. Cancer 47:
2232—2235
Blanco G, Holli K, Heikkinen M, Kallioniemi O-P and Taskinen P (1990) Prognostic
factors in recurrent breast cancer: relationships to site of recurrence, disease-
free interval, female sex steroid receptors, ploidy and histological malignancy
grading. Br J Cancer 62: 142—146
Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF,
Th￿rlimann B, Cavalli F, Obrecht JP, Leyvraz S, Alberto P, Adam H, Varini M,
Loehnert T, Senn HJ, Metzger U and Brunner K (1994) First isolated
locoregional recurrence following mastectomy for breast cancer: results of a
phase III multicenter study comparing systemic treatment with observation
after excision and radiation. J Clin Oncol 12: 2071—2077
Deutsch M, Parsons JA and Mittal BB (1986) Radiation therapy for local-regional
recurrent breast carcinoma. Int J Radiat Oncol Biol Phys 12: 2061—2065
Field SB (1990) In vivo aspects of hyperthermic oncology. In An Introduction to the
Practical Aspects of Clinical Hyperthermia. Field SB and Hand JW (eds.),
pp. 55—68. Taylor and Francis: London
Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR and Fineberg B (1990)
Isolated local-regional recurrence of breast cancer following mastectomy:
radiotherapeutic management. Int J Radiat Oncol Biol Phys 19: 851—858
Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR and Fineberg B (1992)
Survival following locoregional recurrence of breast cancer: univariate and
multivariate analysis. Int J Radiat Oncol Biol Phys 23: 285—291
Results of reirradiation and hyperthermia in breast cancer 489
British Journal of Cancer (1999) 79(3/4), 483–490 © Cancer Research Campaign 1999Hietanen P, Miettinen M and M￿kinen J (1986) Survival after first recurrence in
breast cancer. Eur J Cancer Clin Oncol 22: 913—919
Hurley SF, Huggins RM, Snyder RD and Bishop JF (1992) The cost of breast cancer
recurrences. Br J Cancer 65: 449—455
International Collaborative Hyperthermia Group (1996) Hyperthermia in the
treatment of superficial localized primary and recurrent breast cancer — results
from five randomized controlled trials. Int J Radiat Oncol Biol Phys 35:
731—744
Kapp DS (1996) Efficacy of adjuvant hyperthermia in the treatment of superficial
recurrent breast cancer: confirmation and future directions. Int J Radiat Oncol
Biol Phys 35: 1117—1121
Liu F-F, Bezjak A, Levin W, Cooper B, Pintilie M and Sherar MD (1996) Letter to
the Editor. Assessment of palliation in women with recurrent breast cancer.
Int J Hyperthermia 12: 825—826
Myerson RJ, Perez CA, Emami B, Straube W, Kuske RR, Leybovich L and Von
Gerichten D (1990) Tumor control in long-term survivors following superficial
hyperthermia. Int J Radiat Oncol Biol Phys 18: 1123—1129
Okunieff P, Urano M, Kallinowski F, Vaupel P and Neuringer LJ (1991) Tumors
growing in irradiated tissue: oxygenation, metabolic state, and pH. Int J Radiat
Oncol Biol Phys 21: 667—673
Overgaard J, Gonz￿lez Gonz￿lez D, Hulshof MCCM, Arcangeli G, Dahl O, Mella O
and Bentzen SM (1995) Randomised trial of hyperthermia as adjuvant to
radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345:
540—543
Patanaphan V, Salazar OM and Poussin-Rosillo H (1984) Prognosticators in
recurrent breast cancer. A 15-year experience with irradiation. Cancer 54:
228—234
Perez CA, Gillespie B, Pajak T, Hornback NB, Emami B and Rubin P (1989)
Quality assurance problems in clinical hyperthermia and their impact on
therapeutic outcome: a report by the radiation therapy oncology group. Int J
Radiat Oncol Biol Phys 16: 551—558
Raaphorst GP (1990) Fundamental aspects of hyperthermic biology. In An
Introduction to the Practical Aspects of Clinical Hyperthermia. Field SB and
Hand JW (eds.), pp. 10—54. Taylor and Francis: London
Schwaibold F, Fowble BL, Solin LJ, Schultz DJ and Goodman RL (1991) The
results of radiation therapy for isolated local regional recurrence after
mastectomy. Int J Radiat Oncology Biol Phys 21: 299—310
Stadler B and Kogelnik HD (1987) Local control and outcome of patients irradiated
for isolated chest wall recurrences of breast cancer. Radiother Oncol 8:
105—111
Toonkel LM, Fix I, Jacobson LH and Wallach CB (1983) The significance of
local recurrence of carcinoma of the breast. Int J Radiat Oncol Biol Phys 9:
33—39
Valdagni R, Amichetti M and Pani G (1988) Radical radiation alone versus
radical radiation plus microwave hyperthermia for N3 (TNM-UICC) neck
nodes: a prospective randomized clinical trial. Int J Radiat Oncol Biol Phys 15:
13—24
Van Rhoon GC, Rietveld PJM, Van der Zee J and Van den Berg AP (1998) A 433
MHz Lucite Cone waveguide applicator for superficial hyperthermia. Int J
Hyperthermia 14: 13—27
Van der Zee J and Vernon CC (1996) Thermoradiotherapy for advanced and
recurrent breast tumours. In Medical Radiology. Thermoradiotherapy and
Thermochemotherapy, vol 2. Seegenschmiedt MH, Fessenden P and Vernon
CC (eds.), pp. 35—48. Springer-Verlag: Berlin
Van der Zee J, Van Rhoon GC, Broekmeyer-Reurink MP and Reinhold HS (1987)
The use of implanted closed-tip catheters for the introduction of thermometry
probes during local hyperthermia treatment series. Int J Hyperthermia 3:
337—345
Van der Zee J, Treurniet-Donker AD, The SK, Helle PA, Seldenrath JJ,
Meerwaldt JH, Wijnmaalen AJ, Van den Berg AP, Van Rhoon GC,
Broekmeyer-Reurink MP and Reinhold HS (1988) Low dose reirradiation in
combination with hyperthermia: a palliative treatment for patients with breast
cancer recurring in previously irradiated areas. Int J Radiat Oncol Biol Phys
15: 1407—1413
Van der Zee J, Van Rhoon GC, Koper PCM and Van den Berg AP (1992) Clinical
application and specific requirements of local hyperthermia for chest wall
recurrences. Strahlenther Onkol 168: 653—654
Van der Zee J, Van Rhoon GC, Verloop-van ￿t Hof EM, Van der Ploeg SK, Rietveld
PJM and Van den Berg AP (1993) The importance of adequate heating
techniques for therapeutic outcome. In Hyperthermic Oncology 1992, vol II.
Gerner EW and Cetas CT (eds.), pp. 349—352. Arizona Board of Regents:
Tucson
Van der Zee J, Gonz￿lez Gonz￿lez D, Van Rhoon GC, Van Dijk JDP, Van Putten
WLJ, Hart AAM, Koper PCM, De Wit GA and De Charro FTh (1996) Results
of additional hyperthermia in inoperable pelvic tumours. In Hyperthermic
Oncology 1996. Franconi C, Arcangeli G and Cavaliere R (eds.), pp. 215—217.
Tor Vergata Post Graduate School of Medical Physics: Rome
Withers HR, Peters LJ and Taylor JMG (1995) Dose—response relationship for
radiation therapy of subclinical disease. Int J Radiat Oncol Biol Phys 31:
353—359
490 J van der Zee et al
British Journal of Cancer (1999) 79(3/4), 483–490 © Cancer Research Campaign 1999